Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock | Zendy

William F. McIntyre | Zendy; Kevin J. Um | Zendy; Waleed Alhazzani | Zendy; A. Lengyel | Zendy; Ludhmila Abrahão Hajjar | Zendy; Anthony Gordon | Zendy; François Lamontagne | Zendy; Jeff S. Healey | Zendy; Richard Whitlock | Zendy; Emilie P. BelleyCôté | Zendy

Open Access

Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock

Author(s) -

William F. McIntyre,

Kevin J. Um,

Waleed Alhazzani,

A. Lengyel,

Ludhmila Abrahão Hajjar,

Anthony Gordon,

François Lamontagne,

Jeff S. Healey,

Richard Whitlock,

Emilie P. BelleyCôté

Publication year - 2018

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2018.4528

Subject(s) - medicine , vasopressin , atrial fibrillation , randomized controlled trial , cardiology , shock (circulatory) , anesthesia , adverse effect

Vasopressin is an alternative to catecholamine vasopressors for patients with distributive shock-a condition due to excessive vasodilation, most frequently from severe infection. Blood pressure support with a noncatecholamine vasopressor may reduce stimulation of adrenergic receptors and decrease myocardial oxygen demand. Atrial fibrillation is common with catecholamines and is associated with adverse events, including mortality and increased length of stay (LOS).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research